Loading people...
Ivan Gergel is the Managing Partner and Chief Medical Officer at New Rhein Healthcare Investors, based in Malvern, Pennsylvania. A physician and pharmaceutical executive with over 25 years of industry experience, he has directed clinical efforts resulting in 14 drug approvals. Prior to joining New Rhein in 2017, Gergel served as Chief Medical Officer at Nektar Therapeutics and Executive Vice President of Research and Development at Endo Pharmaceuticals. He previously spent a decade as Senior Vice President of R&D at Forest Laboratories, following early career leadership positions at SmithKline Beecham. Gergel holds an MD from the University of London and an MBA from the Wharton School, and currently serves on the boards of UroGen Pharma and Theranica. His current focus centers on guiding private equity investments in healthcare therapeutics and medical devices that address unmet medical needs.
Ivan Gergel, MD, stands as a distinguished figure in healthcare private equity, serving as a Managing Partner at New Rhein Healthcare Investors. In this pivotal role, Dr. Gergel is instrumental in identifying, evaluating, and executing strategic investments across the healthcare sector, particularly in areas poised for significant growth and innovation. His leadership is central to New Rhein's mission of partnering with established companies to accelerate their development and market impact.
New Rhein Healthcare Investors, under Dr. Gergel's guidance, targets growth equity and buyout opportunities within specialty pharmaceuticals, medical devices, and diagnostics. The firm seeks companies with strong intellectual property, proven market positions, and clear pathways for expansion. Dr. Gergel's deep understanding of the healthcare landscape allows him to identify businesses with high potential for value creation through strategic initiatives, operational enhancements, and targeted mergers and acquisitions. He is particularly adept at recognizing opportunities where scientific innovation meets commercial viability, ensuring that investments contribute to both financial returns and advancements in patient care.
Dr. Gergel brings a wealth of operational and scientific experience to his investment role. Prior to joining New Rhein, he held significant leadership positions in the pharmaceutical industry. Notably, he served as Chief Medical Officer and Executive Vice President, Research & Development at Endo Pharmaceuticals. During his tenure, he played a critical role in product development, regulatory approvals, and portfolio expansion. Before Endo, Dr. Gergel held senior executive roles at Forest Laboratories, where he was instrumental in the development and successful commercialization of numerous pharmaceutical products across various therapeutic areas. His extensive background spans all phases of drug development, clinical research, regulatory affairs, and medical affairs, providing him with a comprehensive perspective on the challenges and opportunities within the healthcare industry. Dr. Gergel is a board-certified psychiatrist, having earned his medical degree from Columbia University College of Physicians and Surgeons and his undergraduate degree from Columbia College.
Through his strategic vision and profound industry knowledge, Dr. Gergel continues to drive New Rhein Healthcare Investors' success, fostering growth in companies that are shaping the future of healthcare. His unique blend of clinical expertise, R&D leadership, and investment acumen makes him a formidable force in the healthcare private equity space.
Ivan Gergel focuses on growth equity and buyout investments in specialty pharmaceuticals, medical devices, and diagnostics. He seeks companies with strong intellectual property and market potential.
Ivan Gergel works as a Managing Partner at New Rhein Healthcare Investors, an organization dedicated to strategic investments within the healthcare sector.
